Best Low Price Stocks For 2015

With shares of Amazon (NASDAQ:AMZN) trading around $282, is AMZN an OUTPERFORM, WAIT AND SEE or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework:

T = Trends for a Stock’s Movement

Amazon serves its customers through its retail websites and focus on selection, price, and convenience. The company also manufactures and sells Kindle devices. Amazon offers programs that enable sellers to sell their products on the company�� websites, including the sellers��own branded websites and fulfill orders through them. It also offers platforms that allow authors, musicians, filmmakers, app developers, and others to publish and sell content. Online commerce has been on the rise because of the convenience, efficiency, and the relatively low prices offered.

Amazon is still dominating the e-commerce world as recent data from the Securities and Exchange Commission seen by the Wall Street Journal shows that brick and mortar retailers are still having a difficult time making headway in online retail. The SEC asked a group of major retailers including Target (NYSE:TGT) and Staples (NASDAQ:SPLS) about their online performance, and data showed that Amazon still sells more online than its next twelve competitors combined.

Best Managed Healthcare Stocks To Invest In Right Now: TiVo Inc.(TIVO)

TiVo Inc., together with its subsidiaries, provides technology and services for television solutions, including digital video recorders (DVRs) and connected televisions in the United States and internationally. The company offers subscription-based TiVo service, which enhances home entertainment by providing consumers with a way to record, watch, and control live television, as well as to receive videos, pictures, and movies from cable, broadcast, and broadband sources in one interface. It also provides a platform for advertising and audience research measurement services. TiVo Inc. distributes the TiVo DVR through consumer electronics retailers and its online store at TiVo.com, as well as the TiVo service through agreements with satellite and cable television service providers; and broadcasting companies. As of January 31, 2011, it had approximately 1.5 million subscriptions to the TiVo service. The company was founded in 1997 and is headquartered in Alviso, California. Advisors' Opinion:

• [By Laura Brodbeck]

  Tuesday

  Earnings Expected: Bob Evans Farms (NASDAQ: BOBE), Analog Devices (NASDAQ: ADI), TiVo (NASDAQ: TIVO), Best Buy (NYSE: BBY), DSW (NYSE: DSW) Sanderson Farms (NASDAQ: SAFM) Economic Releases Expected: U.S. consumer confidence, U.S. house price index, U.S. Redbook, U.S. durable goods orders

  Wednesday

• [By Rick Munarriz]

  5. TiVo needs to take boxing lessons
  TiVo (NASDAQ: TIVO  ) showed strong subscriber growth in its latest quarter, but that's coming entirely from technology licensing deals with cable and satellite television giants.

Best Low Price Stocks For 2015: Benefitfocus Inc (BNFT)

Benefitfocus, Inc., incorporated on March 12, 2013, is a provider of cloud-based benefits software solutions for consumers, employers, insurance carriers, and brokers. The Benefitfocus platform provides an integrated suite of solutions that enables its employer and insurance carrier customers to more efficiently shop, enroll, manage, and exchange benefits information.

The Company�� solutions supports benefits plans, including healthcare, dental, life, and disability insurance, and voluntary benefits plans. The Company provide a multi-tenant cloud-based benefit platform to the employer and carrier markets.

The Company competes with SAP, Oracle, Infor, Aon/Hewitt, Towers Watson, ADP, Paychex, Trizetto and DST Health Solutions.

Advisors' Opinion:

• [By Matt Jarzemsky var popups = dojo.query(".socialByline .popC"); popups.forEach]

  The deal follows a rally in shares of so-called ��loud��software makers like Castlight, which provide their offerings over the Web to subscription-paying customers. Shares of health-records and billing software maker Athenahealth Inc.(ATHN) rallied 83% the year through Thursday. Employee-benefits software firm Benefitfocus Inc.(BNFT) is up 119% since its September IPO, as of the latest close.

Best Low Price Stocks For 2015: Hess Corporation (HES)

Hess Corporation, together with its subsidiaries, operates as an independent energy company worldwide. It operates in two segments, Exploration and Production (E&P), and Marketing and Refining (M&R). The E&P segment explores for, develops, produces, purchases, transports, and sells crude oil and natural gas. This segment conducts exploration and production activities principally in Algeria, Australia, Azerbaijan, Brunei, China, Denmark, Egypt, Equatorial Guinea, France, Ghana, Indonesia, the Kurdistan region of Iraq, Libya, Malaysia, Norway, Peru, the Russian Federation, Thailand, the United Kingdom, and the United States. The M&R segment purchases, markets, and trades in refined petroleum products, natural gas, and electricity. This segment serves motoring public, wholesale distributors, industrial and commercial users, other petroleum companies, governmental agencies, and public utilities. It also operates terminals and retail gasoline stations, which include convenience stores located on the East Coast of the United States. As of December 31, 2012, the company operated 1,361 HESS gasoline stations in New York, New Jersey, Pennsylvania, Florida, Massachusetts, North Carolina, and South Carolina. Hess Corporation was founded in 1920 and is headquartered in New York, New York.

Advisors' Opinion:

• [By Ben Levisohn]

  Yesterday, my colleagues in Asia argued for a bounce back in oil prices and offered some Asian stocks that could benefit if that were to occur. I followed that up with a post for U.S. investors. Now UBS has offered two stock picks of its own that could do well if oil prices recover, but hold up if they don’t: Hess (HES) and Chesapeake Energy (CHK).

Best Low Price Stocks For 2015: Boewe Systec AG (BSY)

BOEWE SYSTEC AG is a Germany-based provider of paper management systems. The Company is primarily engaged in the production of inserting systems, for the secure distribution of printed documents and plastic cards. Its product portfolio also includes plastic card personalization and mailing solutions, software for the monitoring and interconnection of various mailroom systems, paper processing solutions, sorting and mail verification systems, and scanners. The Company developed reading technologies used for cutters, cut sheet feeders, enclosure feeders and inserting systems, which are integrated into its software solutions. BOEWE SYSTEC AG�� products are modular, allowing machinery from different manufacturers to be connected into a production line, offering solutions for the automated mailroom. In addition, the Company provides installation, commissioning and maintenance services, as well as spare parts for its products. Advisors' Opinion:

• [By Inyoung Hwang]

  U.K. stocks erased losses in the last half hour of trading, leaving the FTSE 100 Index (UKX) little changed, as a rally in British Sky Broadcasting Group Plc (BSY) and SABMiller Plc (SAB) offset Dagong Global Credit Rating Co.�� downgrade of U.S. sovereign debt.

• [By Inyoung Hwang]

  BSkyB (BSY) sank 3.3 percent to 822 pence, the biggest slide since May 16, even as the U.K.�� largest pay-TV broadcaster reported sales that topped estimates. The company unveiled a box to link televisions to the Internet and said it will buy back 500 million pounds of shares.

Best Low Price Stocks For 2015: Titan Pharmaceuticals Inc (TTNP.OB)

Titan Pharmaceuticals, Inc., incorporated in February 1992, is a biopharmaceutical company developing therapeutics primarily for the treatment of central nervous system (CNS) disorders. The Company is focused primarily on clinical development of products that include Probuphine for the treatment of opioid addiction; Iloperidone: for the treatment of schizophrenia and related psychotic disorders, and Spheramine for the treatment of advanced Parkinson�� disease. Titan Pharmaceuticals is directly developing its product candidates and also utilizing corporate partnerships, including a collaboration with Bayer Schering Pharma AG, Germany (Bayer Schering) for the development of Spheramine to treat Parkinson�� disease, and Vanda Pharmaceuticals, Inc. (Vanda) for the development of iloperidone for the treatment of schizophrenia and related psychotic disorders.

Probuphine

Probuphine is the first product to utilize the Company�� ProNeura long-ter m drug delivery technology. Probuphine is designed to provide continuous, long-term therapeutic levels of the drug buprenorphine, an approved agent for the treatment of opioid addiction. In December 2007, the Company completed enrollment in a randomized, double-blind, placebo-controlled, multi-center Phase III clinical study of Probuphine in the treatment of opioid addiction. This 150 patient study, which is being conducted in the United States, will evaluate the safety and effectiveness of treatment with Probuphine versus placebo in reducing opioid addiction over 24 weeks of treatment. This study is part of a registration directed program intended to obtain marketing approval of Probuphine for the treatment of opioid addiction in Europe and the United States.

Iloperidone

Iloperidone was evaluated in a Phase III program comprising over 3,500 patients at more than 200 sites in 24 countries, administered and funded by Novartis Pharma AG (Novartis). In three completed efficacy studies conducted by Novartis, ! i! loperidone statistically reduced the symptoms of schizophrenia compared to placebo. Iloperidone has also been investigated in three 12-month safety studies, which confirm safety and tolerability. A dose dependent increase in the Q-T Corrected (QTc) interval was observed and investigated further in a clinical study, and no clinically significant adverse events were observed. In September 2007, Vanda submitted a new drug application (NDA) with the United States Food and Drug Administration (FDA) for iloperidone. The NDA for iloperidone was officially accepted for review by the FDA in November 2007.

Spheramine

Spheramine is a cell-based therapeutic that utilizes the Company�� cell-coated microcarrier (CCM) technology, which enables the development of cell-based therapies for minimally invasive, site-specific delivery to the central nervous system of therapeutic factors precisely where they are needed. Spheramine consists of microcarriers coated wit h human retinal pigment epithelial cells that are intended to enhance brain levels of dopamine, a neurotransmitter deficient in certain brain regions in Parkinson�� disease, leading to movement disorders. Preclinical studies have demonstrated the preliminary efficacy and safety of Spheramine, including blinded studies in a primate model of Parkinson�� disease. In June 2007, enrollment was completed in a current multi-center, randomized, double-blind, placebo-controlled clinical trial of Spheramine in Parkinson�� disease. This Phase IIb clinical study enrolled 71 patients with advanced Parkinson�� disease (Hoehn and Yahr Stages III and IV) to further evaluate the efficacy, safety, and tolerability of Spheramine.

Bayer Schering, the Company�� corporate partner for worldwide development and commercialization of Spheramine, is funding the clinical development program for Spheramine. Under an agreement, Bayer Schering has received exclusive, worldwide deve lopment, manufacturing and commercialization rights, an! d, in! ad! dition! to the clinical and manufacturing development funding and milestone payments, Bayer Schering will pay Titan Pharmaceuticals a royalty on future product sales.

Advisors' Opinion:

• [By C.R. Jackson]

  Fanapt was discovered by Hoechst Marion Roussel in 1995 as a novel atypical antipsychotic agent. Hoechst was a German life-sciences company that became Aventis Deutschland after its merger with France's Rhône-Poulenc in 1999. When the company joined with Sanofi-Synthélabo in 2004, it became a subsidiary of the Sanofi-Aventis (SNY) the French pharmaceutical conglomerate. In 1997, Hoechst sold the research rights to Titan Pharmaceuticals (TTNP.OB). Then Titan quickly sold the worldwide rights to Novartis in 1998. Novartis then sold the Phase 3 development rights for loperidone to Vanda in 2004. Vanda originally attempted to get FDA approval for Fanapt in 2008, but the FDA refused to approve iloperidone. The agency required an additional clinical trial.

Best Low Price Stocks For 2015: IGI Laboratories Inc. (IG)

IGI Laboratories, Inc. engages in developing, manufacturing, filling, and packaging topical semi-solid and liquid products for cosmetic, cosmeceutical, and pharmaceutical customers in the United States. The company�s products are used for various skin conditions, including the treatment of symptoms of dermatitis, acne, psoriasis, and eczema. It offers contract formulation and contract manufacturing services to a range of topical formulations, including creams, ointments, lotions, gels, and topical liquids. The company is also developing a portfolio of prescription generic formulations in topical dosage forms. IGI Laboratories, Inc., through its license agreement with Novavax, Inc., utilizes the Novasome lipid vesicle encapsulation and certain other technologies for applications in animal pharmaceuticals, biologicals, and other animal health products; foods, food applications, nutrients, and flavorings; cosmetics, consumer products, and dermatological over-the-counter and prescription products; fragrances; and chemicals, including herbicides, insecticides, pesticides, paints and coatings, photographic chemicals, and other specialty chemicals. The company was formerly known as IGI, Inc. and changed its name to IGI Laboratories, Inc. in May 2008. IGI Laboratories, Inc. was founded in 1977 and is based in Buena, New Jersey.

Advisors' Opinion:

• [By Holly LaFon]

  The Barclays Aggregate Index rose by 0.57% in 3Q13, having stood at a loss of -0.36% the day before the FOMC's declaration to not slow QE. Despite the bounce, the Index remains in negative territory YTD and for the trailing 12-months at -1.77% and -1.68%, respectively. In stark contrast to 2Q13, Investment Grade (IG) corporate spreads tightened 10bps during 3Q13, producing a positive nominal return of 0.82% and an excess return of 0.92%. The respective YTD total returns in IG remain a disappointing -2.62%, but excess returns are still positive at 0.61% YTD. The 1-Yr results for IG Credit now fall to a nominal -1.58%, but 1.79% in excess of Treasuries.